Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.
暂无分享,去创建一个
E. Green | M. L. Le Beau | K. Shannon | B. Emerling | C. Kratz | J. Bonifas | Jason D. Balkman | Nicole P Curtiss | J. Lauchle | Jennifer Lauchle
[1] M. Loh,et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.
[2] N. Ueda,et al. Molecular Characterization of a Phospholipase D Generating Anandamide and Its Congeners* , 2004, Journal of Biological Chemistry.
[3] Xin Wu,et al. A specific splicing variant of SVH, a novel human armadillo repeat protein, is up-regulated in hepatocellular carcinomas. , 2003, Cancer research.
[4] Junjun Zhang,et al. Human Chromosome 7: DNA Sequence and Biology , 2003, Science.
[5] William Kim,et al. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. , 2003, Current opinion in genetics & development.
[6] Zhijian Qian,et al. Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] E. Green,et al. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia , 2002, Oncogene.
[8] J. Hara,et al. Establishment of a Monosomy 7 Leukemia Cell Line, MONO-7, With aras Gene Mutation , 2002, International journal of hematology.
[9] F. Zindy,et al. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. , 2001, Genes & development.
[10] E. Green,et al. Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. , 2001, Genomics.
[11] S. Reed,et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line , 2001, Nature.
[12] S. Elledge,et al. Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase , 2001, Science.
[13] D. Largaespada,et al. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. , 2001, Seminars in cancer biology.
[14] I. Kurochkin,et al. ALEX1, a novel human armadillo repeat protein that is expressed differentially in normal tissues and carcinomas. , 2001, Biochemical and biophysical research communications.
[15] Michele Pagano,et al. The F-box protein family , 2000, Genome Biology.
[16] J. Herman,et al. Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise. , 2000, Journal of the National Cancer Institute.
[17] J. Gribben,et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. , 2000, Blood.
[18] John M. Maris,et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.
[19] A. Bradley,et al. Congenital heart disease in mice deficient for the DiGeorge syndrome region , 1999, Nature.
[20] S. Scherer,et al. Delineation of multiple deleted regions in 7q in myeloid disorders , 1999, Genes, chromosomes & cancer.
[21] James M. Roberts,et al. The murine gene p27Kip1 is haplo-insufficient for tumour suppression , 1998, Nature.
[22] D. Pinkel,et al. Retention of wild‐type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation , 1998, The EMBO journal.
[23] N. Zeleznik-Le,et al. Establishment and characterization of a megakaryoblast cell line with amplification of MLL , 1998, Leukemia.
[24] P. Nowell,et al. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] S. Scherer,et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. , 1997, Blood.
[26] E. Green,et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. , 1996, Blood.
[27] S. Scherer,et al. Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia. , 1996, Blood.
[28] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[29] A. Bradley,et al. Chromosome engineering in mice , 1995, Nature.
[30] K. Shannon,et al. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. , 1995, Blood.
[31] K. Shannon,et al. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras , 1994 .
[32] P. O'Connell,et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. , 1992, Blood.
[33] E. Liu,et al. Mutations of the ras proto-oncogenes in childhood monosomy 7. , 1991, Blood.
[34] J. Kere,et al. Chromosome 7 long-arm deletions in myeloid disorders: terminal DNA sequences are commonly conserved and breakpoints vary. , 1989, Cytogenetics and cell genetics.
[35] J. Kere,et al. Molecular characterization of chromosome 7 long arm deletions in myeloid disorders. , 1987, Blood.
[36] R. Larson,et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.